Alpha Tau Medical Ltd. (DRTSW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Alpha Tau Medical Ltd. (DRTSW) operates as a clinical-stage oncology therapeutics company dedicated to the research, development, and commercialization of diffusing alpha-emitters radiation therapy, commonly referred to as Alpha DaRT, specifically for treating solid cancers. The company functions within the healthcare sector, focusing on the specialized industry of oncology therapeutics where its proprietary technology is currently undergoing clinical trials for various forms of cancer treatment. In terms of scale, the company employs 121 individuals to support its research and development initiatives, while market capitalization and annual revenue figures are not available in the current financial reporting data. The absence of disclosed market cap and revenue metrics in the available facts suggests that the company may be in a pre-revenue or early-stage commercialization phase, indicating a position focused primarily on advancing clinical data rather than generating immediate sales volume or established market share.

वित्तीय स्वास्थ्य

The company reports a net income of $-42,627,000 and an EBITDA of $-41,056,000, while revenue figures are not available for the trailing twelve months. The significant gap between the reported net income and EBITDA, which differ by approximately $1.57 million, reveals a cost structure heavily influenced by non-operating expenses such as interest or other financial costs that impact the bottom line more than operational cash generation. Free cash flow stands at $-19,703,876, indicating that the company is currently burning cash, which limits its financial flexibility for expansion without securing additional external capital. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, suggesting that either the company has not yet recognized commercial revenue or that its current financial reporting does not reflect positive margins at this stage. The company holds $73.13 million in cash against $13.73 million in debt, resulting in a debt-to-equity ratio of 17.80, which presents a unique balance sheet profile where substantial cash reserves exist alongside a high leverage ratio relative to equity. Despite the high debt-to-equity figure, the current ratio of 7.45 indicates strong short-term liquidity, as the company possesses ample current assets to cover its current liabilities. Return on Equity is reported at -61.0% and Return on Assets at -27.6%, metrics that reveal management is currently generating negative returns on both shareholder equity and total assets, a common characteristic for clinical-stage biotechnology firms investing heavily in R&D before achieving profitability.

मूल्यांकन आकलन

Trailing P/E and forward P/E ratios are not available, meaning standard earnings-based valuation multiples cannot be calculated to assess expected earnings trajectories or market expectations for future profitability. The price-to-book ratio is 0.91, which indicates that the market values the company at approximately 91% of its book value, suggesting a lack of market premium over the net asset value often seen in profitable firms or reflecting investor caution regarding its clinical-stage status. Price-to-sales and EV/EBITDA multiples are also not available due to the lack of revenue and earnings data, preventing alternative valuation comparisons that typically suggest growth potential or operational efficiency. The stock has traded within a narrow range, with a 52-week high of $0.83 and a 52-week low of $0.80. Given these bounds, the current trading price is positioned very close to the upper end of its recent trading range, specifically trading within less than 6% below the 52-week high and approximately 1.2% above the 52-week low. The beta value is 1.05, which implies that the stock's price volatility is slightly higher than the broader market, moving 5% more aggressively than the market index in response to general market movements.

Growth & Income

Revenue growth and earnings growth rates for the year-over-year period are not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue in the recent past. The company does not pay a dividend, as indicated by the absence of a dividend yield and payout ratio, which means the company reinvests all available resources and earnings back into its research, development, and clinical trial programs rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage oncology companies that prioritize funding their Alpha DaRT technology trials over providing current income to investors. The overall growth and income profile is characterized by a lack of historical revenue growth data and zero dividend income, reflecting a capital-intensive business model where value is derived from future clinical approvals rather than current cash flows or shareholder distributions.